NCT05884255 2026-04-17
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
Clinical Trials
9 trialsNCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT04949282 2022-12-23
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
Recruiting
NCT04790708 2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA Unknown
NCT02125474 2019-11-14
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
Instituto Nacional de Cancerologia, Columbia
Phase NA Completed